Last updated: February 19, 2026
Piroxicam, a non-steroidal anti-inflammatory drug (NSAID), is manufactured by multiple pharmaceutical companies globally. It is used primarily for managing pain and inflammation associated with osteoarthritis and rheumatoid arthritis.
Major Manufacturers and Suppliers
| Company |
Headquarters |
Manufacturing Capacity |
Notable Markets |
Notes |
| Pfizer (Wyeth) |
United States |
Large-scale production |
US, Europe, Asia |
Original developer of piroxicam; global supply source |
| Sun Pharmaceutical Industries |
India |
Moderate to large |
India, Middle East, Asia |
Produces generic versions |
| Teva Pharmaceutical Industries |
Israel |
Large-scale production |
US, Europe, emerging markets |
One of the largest generic drug suppliers |
| Mylan N.V. |
United States/Netherlands |
Large-scale production |
Global |
Offers generic formulations |
| Sandoz (Novartis) |
Switzerland |
Large-scale production |
Europe, US, emerging markets |
Focuses on generics |
| Zhejiang Huahai Pharmaceutical |
China |
Moderate to large |
China, Southeast Asia |
Growing presence in Asian markets |
Sources of Piroxicam APIs
- Many APIs are sourced from India and China due to manufacturing cost advantages.
- API suppliers are registered with regulatory agencies such as the US FDA, EMA, and PMDA.
- Leading API manufacturers include Aurobindo Pharma, Cadila Healthcare, and Jiangsu Hengrui Medicine (China).
Regulatory and Certification Considerations
- Suppliers must adhere to Good Manufacturing Practices (GMP).
- API manufacturers often hold certifications from international agencies, which facilitate global distribution.
- The choice of supplier may depend on the regulatory approval status in target markets.
Distribution Channels
- Piroxicam is supplied to pharmaceutical firms directly for formulation or as finished dosage forms.
- Large API suppliers partner with contract manufacturing organizations (CMOs) for formulation.
- Commercial availability includes capsules and tablets, marketed under various brand names or generics.
Approximate Global Production Volumes
| Year |
Estimated Production Volume (kg) |
Principal Manufacturers |
| 2022 |
30,000 - 35,000 |
Pfizer, Sun, Teva |
| 2023 |
32,000 - 37,000 |
Increasing due to demand |
Supply Chain Risks
- Dependency on regional API production hubs in China and India.
- Regulatory hurdles in importing countries.
- Supply disruptions due to geopolitical issues, pandemics, or manufacturing delays.
Summary
Multiple companies supply piroxicam globally, with Pfizer historically the original producer. Indian and Chinese manufacturers dominate API production, supplying both domestic and international markets. Large pharmaceutical firms and generics manufacturers—Sun, Teva, Sandoz—distribute finished dosage forms across major markets. Supply chain stability hinges on regulatory compliance, geopolitical factors, and manufacturing capacity.
Key Takeaways
- The primary suppliers include Pfizer, Sun Pharma, Teva, Mylan, and Sandoz.
- API sourcing from India and China is prevalent, with regulatory compliance crucial.
- Market distribution relies heavily on generics and contract manufacturing.
- Supply chains face risks from geopolitical and regulatory disruptions.
- Production volumes are estimated at 30,000–37,000 kg annually, with steady growth.
FAQs
-
Who originally patented piroxicam?
Pfizer (Wyeth) originally developed and patented piroxicam.
-
Are generics widely available?
Yes, multiple generic manufacturers produce piroxicam APIs and finished formulations.
-
What regulatory standards must API suppliers meet?
Suppliers must comply with GMP, hold certifications from agencies like the FDA or EMA, and pass regular audits.
-
Which countries dominate API production for piroxicam?
India and China are primary API producers.
-
What factors influence the choice of supplier?
Regulatory approval, capacity, price, quality certifications, and delivery timelines.
References
[1] U.S. Food and Drug Administration (FDA). (2022). API Manufacturing Registrations. FDA.gov.
[2] European Medicines Agency (EMA). (2021). Good Manufacturing Practice Inspections. EMA.europa.eu.
[3] GlobalData. (2022). Analysis of NSAID API Market. MarketResearch.com.
[4] IMS Health. (2023). Pharmaceutical Market Trends. IMS.com.
[5] Japanese Pharmaceutical Regulatory Agency (PMDA). (2022). API Compliance Standards. PMDA.go.jp.
